Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06227546 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer

Study acronym: MGC018-SCLC
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Completion pushed from May 2026 to Apr 2027v7
  2. Results first posted: Apr 13, 2026v6
  3. Secondary endpoints revised (5)v5 See this version in full on ClinicalTrials.gov ↗
  4. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 17 to confirmed 9 · Study sites: 3 to 1 · Primary completion date changed from estimate of May 2025 to Mar 28, 2025v4 Show 3 more changesShow less
    • Enrollment target: estimated 17 to confirmed 9
    • Study sites: 3 to 1
    • Primary completion date changed from estimate of May 2025 to Mar 28, 2025
  5. Study sites: 4 to 3v3
  6. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Apr 2024 to Apr 15, 2024 · Eligibility criteria expanded, about 27 words · Site details revised at 4 of 4 sites · 1 morev2 Show 4 more changesShow less
    • Start date changed from estimate of Apr 2024 to Apr 15, 2024
    • Eligibility criteria expanded, about 27 words
    • Site details revised at 4 of 4 sites
    • Study title shortened, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to test MGC018 in patients with relapsed or refractory Extensive-Stage Small-Cell Lung Cancer (ES-SCLC). The main question it aims to answer is: • Does the administration of MGC018 achieve a clinically meaningful response rate of 25% in patients with relapsed or refractory ES-SCLC? Participants enrolled in the trial will receive MGC018 through an intravenous (IV) infusion, every 28 days until disease progression or unacceptable toxicity. Tumor assessment will be done every 2 cycles (28 day cycles). Blood samples will be taken for biomarker analysis before treatment, on cycle 3 day 1, and at progression. A pretreatment biopsies will be done.
Trial Details
NCT Number NCT06227546
Lead Sponsor Georgetown University
Collaborators: MacroGenics
Conditions Extensive-stage Small-cell Lung Cancer
Enrollment 9 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov